Clonal 17p del studies in 21 cases showed significantly higher CXCL13 and galectin-9 plasma levels in CLL patients with positive 17p del compared to the negative 17p del patients (p < 0.002 and p < 0.003, respectively) (Table 1). This evidence concerns the gene CXCL13 and B-cell chronic lymphocytic leukemia.